Matrix Metalloproteinase 2 as a New Marker for Diagnosis of Chronic Kidney Disease

Bibliographic Information
Authors: Alallam A.S.A.; Mohamed A.S.A.; Hassaan M.M.M.; Metwally O.B.; Abdelghany L.R.E.; Abdelaziem O.M.
Journal: Egyptian Journal of Hospital Medicine
Publisher: Ain Shams University Faculty of Medicine
Publication Date: 1 April 2022
Volume / Issue: Volume 87 / Issue 1
Pages: 1288–1292
Article No.: 49
ISSN: 16872002
DOI: 10.21608/ejhm.2022.223320
Scopus: View on Scopus
Document Type: Article
Access: All Open Access; Gold Open Access
Authors and Affiliations
Alallam A.S.A., Department of Internal Medicine, Faculty of Medicine, Zagazig University, Egypt; Mohamed A.S.A., Departments of Nephrology, Theodor Bilharz Research Institute, Egypt; Hassaan M.M.M., Department of Internal Medicine, Faculty of Medicine, Zagazig University, Egypt; Metwally O.B., Department of Clinical Pathology, Theodor Bilharz Research Institute, Egypt; Abdelghany L.R.E., Department of Radiology, Theodor Bilharz Research Institute, Egypt; Abdelaziem O.M., Department of Internal Medicine and Nephrology, Theodor Bilharz Research Institute, Egypt
Abstract
Background: Chronic kidney disease (CKD) is highly prevalent, irreversible, progressive decrease in renal function. Matrix metalloproteinases (MMPs) have an important role in tissue remodelling by regulating cell death, morphogenesis and wound healing activity. Objective: The aim was to assess the diagnostic value of matrix metalloproteinase 2 as a new marker in chronic kidney disease. Patients and Methods: this study was conducted on (108) individuals who were divided into 3 groups of matching age and sex. Group I (Control group): 36 healthy individuals with normal kidney functions. Group II (CKD group): (stage 1-4) 36 subjects with eGFR between 15-89 ml/min/1.73m2. Group III (ESRD group): 36 subjects who were under regular hemodialysis for more than 3 months. Results: There was statistically non-significant difference between the studied groups regarding serum cholesterol. There was statistically significant difference between the studied groups regarding MMP-2. On comparing each two individual groups using Tukey post hoc test for MMP-2, the difference was significant between each two individual groups (MMP-2 was lower in Group I followed by Group II then Group III). The best cutoff of MMP2 in diagnosis of ESRD was ≥0.69615 to <0.78155 with area under curve 0.766, sensitivity 77.8%, specificity 63.9%, positive predictive value (PPV) 68.3%, negative predictive value (NPV) 74.2% and accuracy 70.8%. Conclusion: There was significantly increased levels of MMP-2 in CKD with more increase in ESRD patients. MMP-2 could be used as a marker in diagnosis of CKD. © 2022, Ain Shams University Faculty of Medicine. All rights reserved.
Keywords
Chronic Kidney Disease; Matrix Metalloproteinase 2; New Marker
Citation Information
Scopus Citations: 0
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
